Trials / Completed
CompletedNCT04697719
Body Weight, Aspirin Dose and Pro-resolving Mediators
DISCOVER: A Single-site Double-blind Placebo-controlled Randomized Mechanistic Crossover Trial to Assess the Influence of boDy weIght on aSpirin-triggered speCialized prO-resolVing mEdiatoRs
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 103 (actual)
- Sponsor
- NYU Langone Health · Academic / Other
- Sex
- All
- Age
- 40 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This study employs a placebo-controlled randomized cross-over design to investigate the impact of body weight and aspirin dose on levels of specialized pro-resolving lipid mediators in blood and neutrophils.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aspirin 81mg | 81mg oral capsule |
| DRUG | Aspirin 325mg | 325mg oral capsule |
Timeline
- Start date
- 2021-11-04
- Primary completion
- 2025-01-29
- Completion
- 2025-01-29
- First posted
- 2021-01-06
- Last updated
- 2026-03-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04697719. Inclusion in this directory is not an endorsement.